指南与共识中枢神经肿瘤放疗

IDH突变型2级和3级弥漫性胶质瘤的放射治疗:ASTRO临床实践指南

Radiation Therapy for IDH-Mutant Grade 2 and Grade 3 Diffuse Glioma: An ASTRO Clinical Practice Guideline.
指南 / 共识 · Pract Radiat Oncol · 2022-05-31

美国放射肿瘤学会(ASTRO)组建多学科工作组,针对IDH突变型2级和3级弥漫性胶质瘤的放疗适应证、先进放疗技术和不良反应管理提出推荐。推荐基于系统文献综述和预设的共识构建方法与证据质量及推荐强度分级系统。指南对少突胶质细胞瘤和星形细胞瘤按分级及高危特征分别给出密切观察或辅助放疗的强弱推荐,并给出剂量推荐及先进技术考虑。

要点

  • 少突胶质细胞瘤IDH突变伴1p/19q共缺失、WHO 2级、全切除后无高危特征者,强烈推荐仅密切观察。
  • 少突胶质细胞瘤WHO 2级伴任何高危特征者条件性推荐辅助放疗;WHO 3级者强烈推荐辅助放疗。
  • 星形细胞瘤IDH突变、WHO 2级、全切除后无高危特征者条件性推荐仅密切观察。

核心结论

  • ASTRO工作组基于已发表数据提出推荐,用于指导成人IDH突变型2级和3级弥漫性胶质瘤(按WHO 2021分类)的管理。

研究设计与样本

  • 美国放射肿瘤学会(ASTRO)召集多学科工作组,基于系统文献综述和预设的共识构建方法及证据质量与推荐强度分级系统制定推荐。

主要发现

  • 少突胶质细胞瘤IDH突变伴1p/19q共缺失、WHO 2级、全切除后无高危特征者,强烈推荐仅密切观察。
  • 少突胶质细胞瘤WHO 2级伴任何高危特征者条件性推荐辅助放疗,WHO 3级者强烈推荐辅助放疗。
  • 星形细胞瘤IDH突变、WHO 2级、全切除后无高危特征者条件性推荐仅密切观察,伴任何高危特征者条件性推荐辅助放疗,WHO 3级者强烈推荐辅助放疗。
  • 剂量推荐因组织学类型和分级而异。
  • 考虑放疗已知的长期不良反应,先进技术如调强放疗/容积旋转调强放疗为强烈推荐,质子治疗为条件性推荐。

关键数值与推荐

  • 少突胶质细胞瘤IDH突变伴1p/19q共缺失、WHO 2级、全切除后无高危特征:强烈推荐仅密切观察。
  • 少突胶质细胞瘤WHO 2级伴任何高危特征:条件性推荐辅助放疗。
  • 少突胶质细胞瘤WHO 3级:强烈推荐辅助放疗。
  • 星形细胞瘤IDH突变、WHO 2级、全切除后无高危特征:条件性推荐仅密切观察。
  • 星形细胞瘤IDH突变、WHO 2级伴任何高危特征:条件性推荐辅助放疗;WHO 3级:强烈推荐辅助放疗。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This guideline provides evidence-based recommendations for adults with isocitrate dehydrogenase (IDH)-mutant grade 2 and grade 3 diffuse glioma, as classified in the 2021 World Health Organization (WHO) Classification of Tumours. It includes indications for radiation therapy (RT), advanced RT techniques, and clinical management of adverse effects. METHODS: The American Society for Radiation Oncology convened a multidisciplinary task force to address 4 key questions focused on the RT management of patients with IDH-mutant grade 2 and grade 3 diffuse glioma. Recommendations were based on a systematic literature review and created using a predefined consensus-building methodology and system for grading evidence quality and recommendation strength. RESULTS: A strong recommendation for close surveillance alone was made for patients with oligodendroglioma, IDH-mutant, 1p/19q codeleted, WHO grade 2 after gross total resection without high-risk features. For oligodendroglioma, WHO grade 2 with any high-risk features, adjuvant RT was conditionally recommended. However, adjuvant RT was strongly recommended for oligodendroglioma, WHO grade 3. A conditional recommendation for close surveillance alone was made for astrocytoma, IDH-mutant, WHO grade 2 after gross total resection without high-risk features. Adjuvant RT was conditionally recommended for astrocytoma, WHO grade 2, with any high-risk features and strongly recommended for astrocytoma, WHO grade 3. Dose recommendations varied based on histology and grade. Given known adverse long-term effects of RT, consideration for advanced techniques such as intensity modulated radiation therapy/volumetric modulated arc therapy or proton therapy were given as strong and conditional recommendations, respectively. Finally, based on expert opinion, the guideline recommends assessment, surveillance, and management for toxicity management. CONCLUSIONS: Based on published data, the American Society for Radiation Oncology task force has proposed recommendations to inform the management of adults with IDH-mutant grade 2 and grade 3 diffuse glioma as defined by WHO 2021 classification, based on the highest quality published data, and best translated by our task force of subject matter experts.

来源:Pract Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Halasz LM, Attia A, Bradfield L, et al. Radiation Therapy for IDH-Mutant Grade 2 and Grade 3 Diffuse Glioma: An ASTRO Clinical Practice Guideline. Pract Radiat Oncol. 2022. PMID: 35902341. doi:10.1016/j.prro.2022.05.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。